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AbstrACt
background Several cancer types harbor alterations in 
the gene encoding AT- Rich Interactive Domain- containing 
protein 1A (ARID1A), but there are no approved therapies 
to address these alterations. Recent studies have shown 
that ARID1A deficiency compromises mismatch repair 
proteins. Herein, we analyzed 3403 patients who had 
tumor tissue next- generation sequencing.
Findings Among nine cancer subtypes with >5% 
prevalence of ARID1A alterations, microsatellite instability- 
high as well as high tumor mutational burden was 
significantly more frequent in ARID1A- altered versus 
ARID1A wild- type tumors (20% vs 0.9%, p<0.001; 
and 26% vs 8.4%, p<0.001, respectively). Median 
progression- free survival (PFS) after checkpoint blockade 
immunotherapy was significantly longer in the patients 
with ARID1A- altered tumors (n=46) than in those with 
ARID1A wild- type tumors (n=329) (11 months vs 4 
months, p=0.006). Also, multivariate analysis showed that 
ARID1A alterations predicted longer PFS after checkpoint 
blockade (HR (95% CI), 0.61 (0.39 to 0.94), p=0.02) and 
this result was independent of microsatellite instability 
or mutational burden; median overall survival time was 
also longer in ARID1A- altered versus wild- type tumors 
(31 months vs 20 months), but did not reach statistical 
significance (p=0.13).
Conclusions Our findings suggest that ARID1A alterations 
merit further exploration as a novel biomarker correlating 
with better outcomes after checkpoint blockade 
immunotherapy.
IntroduCtIon
The ARID1A gene encoding AT- Rich Interac-
tive Domain- containing protein 1A is known 
as a member of the switching/sucrose non- 
fermentable (SWI/SNF) complex involved 
in chromatin remodeling.1 Mutations in 
and loss of the ARID1A gene mostly lead to 
its inactivation and ARID1A protein loss.2 
Certain types of cancer, including clear cell 
ovarian carcinoma (46%–50%), gastric 
adenocarcinoma (10%–35%), and chol-
angiocarcinoma (15%–27%), frequently 
harbor ARID1A alterations.2–4 To date, 
clinical and preclinical data indicate that 
ARID1A alterations may sensitize tumors to 
drugs targeting the ataxia telangiectasia and 
Rad3- related (ATR) protein, the enhancer of 
zeste 2 (EZH2), or the phosphatidylinositol-
3- kinase (PI3K) pathway,5–10 but no thera-
pies targeting ARID1A alterations have been 
approved. Importantly, Shen et al demon-
strated that ARID1A alterations interact with 
the mismatch repair (MMR) protein MSH2 
and, hence, compromise MMR.3 Tumors 
formed by an ARID1A- deficient ovarian 
cancer cell line in syngeneic mice exhibited 
higher mutation load, as well as increased 
numbers of tumor- infiltrating lymphocytes 
and elevated programmed cell death- ligand 
1 (PD- L1) expression. Furthermore, admin-
istration of anti- PD- L1 antibody decreased 
cancer burden and extended survival of mice 
bearing ARID1A- deficient but not ARID1A 
wild- type ovarian tumors.3 Interestingly, alter-
ations in the polybromo-1 (PBRM1) gene, 
which is another member of the SWI/SNF 
complex, have been reported to correlate with 
salutary effects in cancer patients receiving 
checkpoint blockade inhibitors, though the 
clinical evidence remains controversial.11 12 In 
gastric cancers, ARID1A alterations are associ-
ated with Epstein- Barr virus infection, which 
is in turn associated with checkpoint blockade 
response.13 Herein, for the first time to 
our knowledge, we investigated the clinical 
correlation between ARID1A alterations and 
treatment benefit after anti- programmed cell 
death-1 (PD-1)/PD- L1 immunotherapy in 
the human pan- cancer setting.
MAterIAls And Methods
study population and next-generation sequence
In a cohort of 3403 eligible patients at the 
Center for Personalized Cancer Therapy 
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(University of California San Diego Moores Cancer 
Center), whose tissue DNA was analyzed by next- 
generation sequencing (NGS) by Foundation Medicine, 
Inc. (CLIA- licensed and CAP- accredited laboratory. 
Cambridge, Massachusetts, USA https://www. founda-
tionmedicine. com), we reviewed the clinicopatholog-
ical and genomic information of patients whose tumors 
were pathologically diagnosed as one of nine types of 
cancer that frequently harbored ARID1A alterations 
(>5% of prevalence in this cohort): non- small cell lung 
cancer, colorectal adenocarcinoma, breast cancer, mela-
noma, pancreatic ductal adenocarcinoma, cholangiocar-
cinoma/hepatocellular carcinoma, gastric/esophageal 
adenocarcinoma, uterine/ovary endometrial (endome-
trioid) carcinoma (including clear- cell carcinoma), and 
urothelial bladder carcinoma. Tissue DNA sequencing 
at the laboratory was approved by the US Food and 
Drug Administration in November 2017 and designed 
to include all genes somatically altered in human solid 
malignancies that were validated as targets for therapy, 
either approved or in clinical trials, and/or that were 
unambiguous drivers of oncogenesis based on available 
knowledge.14 15 Although the gene panel expanded with 
time (236–324 genes), the interrogation of the ARID1A 
gene was considered consistent. Only characterized 
ARID1A alterations were considered in this study (vari-
ants of unknown significant were excluded). In terms of 
microsatellite instability (MSI) status, 114 intron homo- 
polymer repeat loci with adequate coverage are analyzed 
for length variability and compiled into an overall score 
via principal components analysis.16 17 Measuring genes 
interrogated on the tissue DNA NGS and extrapolating to 
the genome as a whole as previously validated determined 
tumor mutational burden (TMB).18 TMB was classified to 
three categories: high (≥20 mutations/mb), intermediate 
(6–19 mutations/mb), and low (<6 mutations/mb).
statistics
Using the Mann- Whitney U test and Fisher’s exact test, 
respectively, we compared categorical and continuous 
data. Progression- free survival (PFS) and overall survival 
(OS) data were measured from date of the initiation of 
Figure 1 (A) Prevalence of characterized ARID1A alterations in tissue DNA NGS according to cancer types (n=1540). 
(B) Frequency of MSI- high according to ARID1A status (microsatellite status was available in 1093 patients (71.0%)). (C) 
Frequency of TMB- high according to ARID1A status (TMB- status was available in 1411 patients (91.6%); p values are for 
TMB- high rates): TMB- high (≥20 mutations/mb); TMB- intermediate (6–19 mutations/mb); TMB- low (<6 mutations/mb). ARID1A, 
AT- Rich Interactive Domain- containingprotein 1A; bladder, urothelial bladder carcinoma; breast, breast cancer; cholangio/
HCC, cholangiocarcinoma and hepatocellular carcinoma; colorectal, colorectal adenocarcinoma; endometrial, uterine/ovary 
endometrial (endometrioid) carcinoma; gastroesophageal, gastric/esophageal adenocarcinoma; MSI, microsatellite instability; 
NGS, next- generation sequencing; NSCLC, non- small cell lung cancer; pancreatic, pancreatic ductal adenocarcinoma; TMB, 
tumor mutational burden.
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anti- PD-1/PD- L1 immunotherapy and plotted by the 
Kaplan- Meier method. Data were censored if patient was 
progression free or alive (for PFS and OS, respectively) 
at last follow- up. The curves were compared by using the 
log- rank test. In multivariate analysis to investigate inde-
pendent predictive factors for the PFS after anti- PD-1/
PD- L1 immunotherapy, we used Cox’s proportional 
hazard model for estimating HR and its 95% CI (variables 
with p<0.1 in the univariate analyses were entered into 
the multivariate analysis). RO performed and verified 
statistical analysis using SPSS V.24 software.
results And dIsCussIon
Starting with 3403 eligible patients who underwent tissue 
DNA NGS, we found 1540 patients with nine types of 
cancer diagnoses that had >5% prevalence of character-
ized ARID1A alterations in tissue DNA NGS (figure 1A 
and online supplementary figure 1). Of 161 patients with 
≥1 characterized ARID1A alteration in diverse types of 
cancer, 142 had ARID1A substitution or frameshift alter-
ations, while the remaining 19 had insertions, deletions, 
allelic loss, rearrangement, or truncation. Endometrial 
and gastroesophageal cancers were the tumor types in 
which ARID1A alterations were most frequent—49% 
and 20% of cases, respectively (figure 1A). The median 
number of genomic coalterations among tumors with 
ARID1A alterations was 6 (range, 1–72) (not including 
ARID1A alterations), which was significantly higher than 
the median of 4 alterations (range, 0–61) among those 
cancers with wild- type ARID1A (p<0.001). The rate of 
MSI- high was significantly higher in tumors with ARID1A 
alterations than in those with wild- type ARID1A (20% vs 
0.9%; p<0.001) and in multiple individual tumor types as 
well (eg, MSI- high in ARID1A- altered vs wild- type endo-
metrial cancer, 41% vs 0%, p=0.001) (figure 1B). Simi-
larly, TMB- high (≥20 mutations/mb) was more often 
observed in tumors with ARID1A alterations than in those 
with wild- type ARID1A (26% vs 8.4%; p<0.001) and in 
individual tumor types (eg, endometrial cancer, 35% vs 
0%, p=0.001) (figure 1C).
Overall, 375 patients (24%) among the 1540 patients 
with the nine types of cancer with >5% ARID1A alter-
ations received anti- PD-1/PD- L1 immunotherapy in the 
advanced/metastatic disease setting (see online supple-
mentary figure 1). MSI- high and TMB- high were seen 
in 4.3% (n=16) and 17% (n=65) of these 375 patients, 
respectively. As shown in figure 2A, patients with ARID1A- 
altered tumors showed a significantly longer PFS than 
those with the wild- type tumors (10.9 months vs 3.9 
months, p=0.006) from the start of anti- PD-1/PD- L1 
immunotherapy. When PFS was analyzed according to 
cancer diagnosis (only tumor types with ≥5 patients with 
ARID1A alterations), similar sensitivity was observed in 
individual tumor types (eg, colorectal cancer (5.2 months 
vs 2.1 months, p=0.005); endometrial cancer (4.6 months 
vs 3.0 months, p=0.02)) (see online supplementary 
figure 2). Importantly, even when only patients without 
MSI- high were included to the analysis, ARID1A- altered 
tumors showed a significantly longer PFS than those with 
wild- type tumors: HR (95% CI), 0.62 (0.40 to 0.97); p=0.03 
(figure 2B). In the same way, when only patients without 
TMB- high were included to the analysis, patients with 
ARID1A- altered tumors (vs ARID1A wild- type) showed 
a trend towards longer PFS: HR (95% CI), 0.69 (0.43 
to 1.08) although not statistically significant (p=0.10) 
(see online supplementary figure 3) (small numbers of 
patients precluded analysis of patients with MSI- high or 
TMB- high who had ARID1A alterations vs not). When 
examining OS in ARID1A- altered versus the wild- type 
patients, median OS time was longer in the ARID1A- 
altered group (30.8 months vs 20 months), but this did 
not reach statistical significance (p=0.13) (see online 
Figure 2 Kaplan- Meier curve of PFS according to ARID1A status. (A) Among patients who received anti- programmed cell 
death-1 (PD-1)/programmed cell death- ligand 1 (PD- L1) immunotherapy (n=375). (B) Among patients without microsatellite 
instability- high who received anti- PD-1/PD- L1 immunotherapy (n=359). Similar results were seen even if the MS- unknown 
(n=60) were excluded (p=0.02). ARID1A, AT- Rich Interactive Domain- containingprotein 1A; MS, microsatellite status; PFS, 
progression- free survival.
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Table 1 Characteristics of patients who underwent anti- PD-1/PD- L1 immunotherapy (n=375)
Variables
ARID1A- altered
(n=46)
ARID1A- wild type
(n=329) P value
Basic characteristics and tissue DNA next- generation sequencing
Age at tissue DNA analysis, years
  Median (range) 65.1 (34.0–89.4) 63.0 (22.3–93.7)   0.49
Gender   
  Female 25 (54.3%) 142 (43.2%)   0.16
  Male 21 (45.7%) 187 (56.8%)   –
Diagnosis   
  Lung cancer, non- small cell 7 (15.2%) 104 (31.6%)   0.02
  Colorectal adenocarcinoma 12 (26.1%) 37 (11.2%)   0.009
  Breast cancer 1 (2.2%) 24 (7.3%)   0.34
  Melanoma 6 (13.0%) 91 (27.7%)   0.046
  Pancreatic ductal adenocarcinoma 1 (2.2%) 7 (2.1%)   >0.99
  Cholangiocarcinoma/hepatocellular carcinoma 2 (4.3%) 13 (4.0%)   0.71
  Gastric/esophageal adenocarcinoma 5 (10.9%) 16 (4.9%)   0.16
  Endometrial carcinoma 10 (21.7%) 13 (4.0%)   <0.001
  Urothelial bladder carcinoma 2 (4.3%) 24 (7.3%)   0.76
Characterized alterations
  Median (range) 8 (2–57)* 5 (1–24)   <0.001
Microsatellite status   
  MSI- high 13 (28.3%) 3 (0.9%)   <0.001
  Stable 31 (67.4%) 268 (81.5%)   0.03
  Unknown 2 (4.3%) 58 (17.6%)   0.02
Tumor mutational burden, mutations/mb   
  Median (range)† 16.0 (1.0–321.0) 6.1 (0.0–222.0)   <0.001
  ≥20 (high) 18 (39.1%) 47 (14.3%)   <0.001
  6–19 (intermediate) 16 (34.8%) 129 (39.2%)   0.63
  <6 (low) 8 (17.4%) 133 (40.4%)   0.002
  Unknown 4 (8.7%) 20 (6.1%)   0.52
Anti- PD-1/PD- L1 immunotherapy
Administered as   
  1st line 8 (17.4%) 113 (34.3%)   0.03
  ≥2nd line 38 (82.6%) 216 (65.7%)   –
Regimen of anti- PD-1/PD- L1 immunotherapy   
  Anti- PD-1/PD- L1 monotherapy 25 (54.3%) 170 (51.7%)   0.76
  With molecular targeting drug 7 (15.2%) 36 (10.9%)   0.46
  With CTLA4 inhibitor 6 (13.0%) 56 (17.0%)   0.67
  With cytotoxic chemotherapy 4 (8.7%) 33 (10.0%)   >0.99
  With molecular targeting and cytotoxic drugs 2 (4.3%) 2 (0.6%)   0.08
  Others‡ 2 (4.3%) 32 (9.7%)   0.41
All p- values <0.05 are listed in bold.
*Excluded ARID1A alterations.
†Among 1411 patients whose TMB data were available.
‡With NKG2A inhibitor (n=9); with CD73 inhibitor (n=8); with IDO1 inhibitor (n=6); with CD122- preferential IL-2 pathway agonist (n=5); with CTLA4 
inhibitor and molecular targeting drug (n=2); with OX40 agonist (n=2); with CEA/BiTE inhibitor (n=1); with 4- 1BB inhibitor (n=1).
ARID1A, AT- Rich Interactive Domain- containing protein 1A gene; bladder, urothelial bladder carcinoma; breast, breast cancer; cholangio/HCC, 
cholangiocarcinoma and hepatocellular carcinoma; colorectal, colorectal adenocarcinoma; CTLA4, cytotoxic T lymphocyte antigen 4; endometrial, 
uterine/ovary endometrial (endometrioid) carcinoma; gastroesophageal, gastric/esophageal adenocarcinoma; MSI, microsatellite instability; NSCLC, 
non- small cell lung cancer; pancreatic, pancreatic ductal adenocarcinoma; PD-1/PD- L1, programmed cell death-1 and its ligand.
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supplementary figure 4). In order to better determine if 
the correlation between ARID1A alterations and longer 
PFS was independent of specific confounding variables, 
we performed a multivariate analysis (patient character-
istics of ARID1A- altered vs wild- type patients are shown 
in table 1). Our Cox- regression model demonstrated 
that ARID1A alterations were selected as an independent 
predictor of better outcome (PFS) after anti- PD-1/PD- L1 
immunotherapy (HR (95% CI), 0.61 (0.40 to 0.94); 
p=0.03) (table 2).
In conclusion, 28% of ARID1A- altered tumors (n=32 
of 114 patients whose microsatellite and TMB status 
were both available) had either MSI- high or TMB- high 
(or both), and the rate of MSI- high and TMB- high was 
significantly higher in ARID1A- altered versus wild- type 
tumors. These findings are consistent with previous 
reports that ARID1A deficiency is correlated with MMR 
deficiency.3 19 ARID1A alterations were independently 
and significantly associated with longer PFS after anti- 
PD-1/PD- L1 immunotherapy (regardless of microsatel-
lite and TMB status). This study has several limitations 
such as the small number of patients with each cancer 
type, which restricted our ability to analyze individual 
tumor histologies. Nevertheless, the results suggest 
generalizability across tumor types. Another limitation 
was that improvement in OS in ARID1A- altered patients 
(vs wild- type) did not reach statistical significance; larger 
numbers of patients are needed to validate this endpoint. 
Therefore, ARID1A alterations may be a genomic marker 
of checkpoint blockade sensitivity, in addition to other 
putative markers such as MSI- high and TMB- high.20–22 
Our observations indicate that ARID1A alterations 
warrant further studies with longer follow- up and larger 
numbers of patients in order to confirm if they can be 
added to the armamentarium of genomic markers that 
are exploitable for matching patients to immunotherapy 
in the pan- cancer setting.23 24
Contributors Study conception and design: RO, SK, JKS, and RK; data acquisition: 
RO, SL, and REJ; statistical analysis: RO and SK; data interpretation: RO, SK, JKS, 
and RK; drafting the manuscript or revising it critically: all authors; final approval of 
the manuscript: all authors.
Table 2 Univariate and multivariate analyses for progression- free survival after anti- PD-1/PD- L1 immunotherapy (n=375). 
Variables with p<0.10 in the univariate analyses were entered into the multivariate analysis
Characteristics
Progression- free survival
Univariate analysis Multivariate analysis
Median, months P value HR (95% CI) P value
Age, years*
  ≥63 (n=195) vs <63 (n=180) 4.6 vs 4.0 0.57 – –
Gender
  Female (n=167) vs male (n=208) 3.8 vs 5.1 0.08 1.16 (0.91 to 1.47) 0.23
Diagnosis
  NSCLC (n=111) vs not (n=264) 4.9 vs 4.1 0.99 – –
  Colorectal (n=49) vs not (n=326) 2.9 vs 4.6 0.02 1.38 (0.98 to 1.97) 0.07
  Melanoma (n=97) vs not (n=278) 7.8 vs 3.7 <0.001 0.69 (0.50 to 0.95) 0.02
  Endometrial (n=23) vs not (n=352) 3.7 vs 4.2 0.64 – –
Number of characterized alteration in tissue DNA†
  ≥6 (n=195) vs <6 (n=180) 4.2 vs 4.2 0.03 1.09 (0.84 to 1.41) 0.51
MSI- status
  MSI- high (n=16) vs not‡ (n=359) 12.3 vs 4.0 0.01 0.74 (0.33 to 1.64) 0.46
TMB, mutations/mb
  TMB- high (≥20) (n=65) vs not‡ (n=310) 13.6 vs 3.7 <0.001 0.47 (0.31 to 0.71) <0.001
ARID1A status
  ARID1A- altered (n=46) vs wild type (n=329) 10.9 vs 3.9 0.006 0.61 (0.39 to 0.94)§ 0.02
Regimen of anti- PD-1/PD- L1 immunotherapy
  Administered as 1st line (n=121) vs ≥2nd line (n=254) 7.4 vs 3.7 0.001 0.80 (0.60 to 1.07) 0.13
All p- values <0.05 are listed in bold.
*Age at tissue DNA analysis. Dichotomized by the median.
†Dichotomized by the median.
‡Including patients whose data were not reported.
§The HR (95% CI) was similar (0.55 (0.34 to 0.88), p=0.01) even if patients with MS- unknown or TMB- unknown (n=70) were excluded.
ARID1A, AT- Rich Interactive Domain- containing protein 1A gene; CI, confidence interval; HR, hazard ratio; MSI, microsatellite instability; 
NSCLC, non- small cell lung cancer; PD-1/PD- L1, programmed cell death-1 and its ligand; TMB, tumor mutational burden.
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